TEAMMATE Trial: Everolimus with Low-Dose Tacrolimus to Prevent Rejection in Children after Cardiac Transplantation
Key Points This was the first randomized trial to evaluate the safety…
ATTRibute-CM: Acoramidis Linked to Improved clinical outcomes in transthyretin amyloid cardiomyopathy
Key Points: Transthyretin amyloid cardiomyopathy develops because of mis-folded proteins infiltrating the…
QUEST: Chinese Herbal Medicine (Qiliqiangxin) reduces heart failure hospitalizations and cardiovascular mortality in HFrEF
Key Points: Qiliqiangxin is a traditional Chinese herbal medicine extract which has…
Wait no more – HFrEF patients with high RV pacing burden from pacemakers or defibrillators should be promptly upgraded to CRT devices: insights from the BUDAPEST-CRT Upgrade Study
Key Points: A high burden of right ventricular pacing among patients with…
PRO-HF Sub-Study: Routine KCCQ-12 assessments in HF improves accuracy of provider assessment of patient health status.
Key Points Clinicians estimate heart failure (HF) health status using New York…
ECMO-CS: Early ECMO Does not Improve Outcomes in Severe Cardiogenic Shock
Key Points: ECMO has been used as a salvage strategy in severe…
IRONMAN: Intravenous Ferric Derisomaltose did not not meet primary endpoint in HFrEF
Key Points: Iron deficiency is common and a poor prognostic feature in…
COACH – A Patient-Risk Based Health System Intervention for Acute Heart Failure Care: The Comparison of Outcomes and Access to Care for Heart Failure (COACH) Trial
Key Points: HF patients frequently present to the ED for acute exacerbations,…
First-in-Human in vivo Crispr/Cas9 Editing of the TTR Gene by NTLA-2001 in patients with Transthyretin Amyloid Cardiomyopathy
Key Points: Transthyretin Amyloidosis (ATTR) is a highly morbid and often fatal…
Does Loop Diuretic Type Affect Clinical Outcomes in Heart Failure? Furosemide vs. Torsemide Compared in the TRANSFORM-HF Trial
Key points: Loop diuretics are routinely used to manage congestion in heart…
Role for Omecamtiv Mecarbil in Pts with EF
KEY POINTS: An experimental new therapeutic for heart failure, omecamtiv mecarbil is…
Hospital-level Intervention Did Not Improve Outcomes or Quality in HFrEF
Key Points: CONNECT-HF, one of the largest heart failure (HF) implementation science…
Pirfenidone Shown to Decrease Fibrosis in Patients with HFpEF
Key Points: Myocardial fibrosis has previously been associated with death and repeat…
Sacubitril/Valsartan Not More Effective Than Valsartan alone in Advanced HF: LIFE trial
Key Points: This is the first study to assess the effects of…
REHAB-HF: A Novel Physical Rehabilitation Intervention For Older Patients With ADHF
Key Points: Elderly frail patients with acute decompensated heart failure hospitalizations benefit…
Are ACE Inhibitors or Beta-Blockers Cardioprotective During Adjuvant Treatment for Early-Stage Breast Cancer?
New results were presented from the Prevention of Cardiac Dysfunction During Adjuvant…
PRADA: Cardioprotective Agents May Not Be Required During Breast Cancer Tx
Adjuvant breast cancer therapy, while beneficial in prolonging survival, has been shown…
Tricuspid Valve Replacement with the Transcatheter Evoque Valve is Safe and Effective at 30 days
Transcatheter tricuspid valve replacement has become a feasible alternative to surgery in…
Prospective ARNI Versus Ace Inhibitor Trial to Determine Superiority In Reducing Heart Failure Events After Myocardial Infarction (PARADISE-MI)
KEY POINTS Sacubitril/valsartan did not provide a lower rate of cardiovascular death,…
EXPLORER-HCM Trial: Mavacamten Associated With Significant Improvement in Patients’ Health Status in Patients With Symptomatic LV Outflow Tract Obstruction
EXPLORER-HCM presented at the American College of Cardiology 2021 meeting by John…